Orthopaedic Synergy, Inc. Announces Key Additions to the Board of Directors

EAST TAUNTON, Massachusetts, May 20, 2013 /PRNewswire/ -- The Board of Directors of Orthopaedic Synergy, Inc. ("OSI")  whose subsidiary companies include OMNIlife science®, Inc., Enztec, Ltd., and Praxim, SA, have elected two experienced directors to their Board.  Guy Mayer, an experienced orthopaedic executive, will serve as the Chairman of the Board of Directors and David Johnson, an established medical device expert, will join as a director.

Before joining OSI as Board Chairman, Mr. Mayer served as President and Chief Executive Officer of Ascension Orthopedics, Inc. until it was acquired by Integra Life Science Holdings Corporation.  Prior to that role, Mr. Mayer was President, Chief Executive Officer and a Director of Tutogen Medical, Inc. where he played an instrumental role in the sale of Tutogen to RTI Biologics, Inc.  Mr. Mayer has also served as President and CEO of several other well known companies in the pharmaceutical and orthopaedic industry, including as President of Zimmer's Global Products Group. Currently Mr. Mayer also sits on the Board of Directors of Pivot Medical, Inc.

"I welcome the opportunity to serve as Chairman of OSI's Board of Directors, and look forward to working with the newly formed Board and the executive teams at OMNI, Enztec and Praxim.  While assisting OSI to deliver on the corporate mission and goals, I plan to focus on the strategic development and governance necessary to take the next step in the evolution of OSI and its subsidiaries," Mr. Mayer said in accepting his appointment.

The Board of Directors also appointed David Johnson as a Board member.  Mr. Johnson joins the Board with a broad spectrum of corporate management expertise and over 30 years experience leading private and public medical device companies.  Most recently he served as Chief Executive Officer of ConvaTec, Inc. Prior to this position he held senior level positions with Zimmer, Inc., Fisher Scientific, and Baxter Corporation.  He currently serves on the Board of Directors of Alliqua, Inc. 

George Cipolletti, Omni's Chief Executive Officer, stated he was thrilled with the additions of Guy and Dave to the Board of Directors. "They bring a wealth of strategic and industry experience that will help to facilitate the implementation of our aggressive growth initiatives.  Their business relationships and knowledge relating to strategic transactions, private equity and the capital markets will greatly benefit the company as we move forward."

About Orthopaedic Synergy, Inc.
Orthopaedic Synergy, Inc. functions as a holding company for its subsidiaries, OMNIlife science, Inc., (USA) Enztec Limited (New Zealand) and PRAXIM, SA. (France). Together these companies represent a global reconstructive orthopaedic concern that is committed to improving clinical outcomes through the design, manufacture and global distribution of high quality orthopaedic implants, as well as instrumentation and computer and robotics based surgical delivery systems for those implants. Providing a business and financial environment that encourages innovation, engineering excellence and shared business success in our subsidiary companies is the cornerstone of our corporate philosophy.   Additional information can be found at www.orthopedicsynergy.com.

About OMNIlife science, Inc.
OMNIlife science, Inc. was founded in 1999 as an organization committed to the design, manufacture and distribution of high quality orthopaedic devices. Our corporate headquarters are located in East Taunton, Massachusetts.  Our products are prescribed by orthopaedic surgeons for their patients who require total joint replacement.  OMNI is ISO 13485 certified and its products are FDA cleared and CE approved.  OMNI is emerging as a leader in modular hip stem technology and total knee replacement systems. We continue to challenge the design and functionality of our products based on continued advances in reconstructive surgical techniques, anatomic and biomechanical data, as well as input from surgeons. Our corporate strategic objectives include continued growth through line extensions to our hip and knee product offerings as well as the introduction of new products that will complement our current product portfolio and allow us to provide new clinical options for our customers. Additional information can be found at www.omnils.com.